DJI136 not checked

Novartis

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.”In the company’s words, NCT07564401 on ClinicalTrials.gov
Tested for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Main trialPhase 1/2
“This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.”In the company’s words, NCT07564401 on ClinicalTrials.gov

Other drugs for Extensive-stage Small Cell Lung Cancer (ES-SCLC)

All 118 drugs for Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 3 Mar 2031 A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow DJI136

Following is part of Solo: you see every change to DJI136 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in